Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

(2022) Laura Vangeel et al.   ANTIVIRAL RESEARCH

Booster Vaccination to Prevent COVID-19 in the Era of Omicron

(2022) Saad B. Omer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

(2022) Jennifer Hammond et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality)

(2022) Lisa Pilgram et al.   INFECTION

Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge

(2022) Nicholas Piccicacco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hospitalized patients dying with SARS-CoV-2 infection—An analysis of patient characteristics and management in ICU and general ward of the LEOSS registry

(2022) Claudia Raichle et al.   PLoS One

Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness

(2021) Oksana Martinuka et al.   CLINICAL MICROBIOLOGY AND INFECTION

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

(2021) Obbina Abani et al.   LANCET

Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19

(2021) Brian T. Garibaldi et al.   JAMA Network Open

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

(2021) Florence Ader et al.   LANCET INFECTIOUS DISEASES

Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned

(2021) Lars Dölken et al.   Viruses-Basel

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

(2021) Vincent C Marconi et al.   Lancet Respiratory Medicine

Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience

(2021) Alessandro Russo et al.   Journal of Clinical Medicine

Anticoagulation in COVID-19

(2021) Charlotte A Bradbury et al.   LANCET

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

(2021) Angélica Jayk Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

(2021) Robert L. Gottlieb et al.   NEW ENGLAND JOURNAL OF MEDICINE

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

(2021) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

(2021) Anil Gupta et al.   NEW ENGLAND JOURNAL OF MEDICINE

The race between vaccination and evolution of COVID-19 variants

(2021) Talha Khan Burki   Lancet Respiratory Medicine

Die COVID-19 Pandemie als Herausforderung und Chance für Register in der Versorgungsforschung: Erfahrungen aus Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS)

(2021) Lisa Pilgram et al.   GESUNDHEITSWESEN

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

(2020) Jason D. Goldman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compassionate Use of Remdesivir for Patients with Severe Covid-19

(2020) Jonathan Grein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

(2020) Spinello Antinori et al.   PHARMACOLOGICAL RESEARCH

Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study

(2020) Christian Karagiannidis et al.   Lancet Respiratory Medicine

Randomized Controlled Trials vs Real-World Data in the COVID-19 Era: A False Narrative

(2020) Gary H Lyman et al.   CANCER INVESTIGATION

Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study

(2020) Irit Nachtigall et al.   CLINICAL MICROBIOLOGY AND INFECTION

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

(2020) Christoph D. Spinner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Virology, transmission, and pathogenesis of SARS-CoV-2

(2020) Muge Cevik et al.   BMJ-British Medical Journal

A living WHO guideline on drugs for covid-19

(2020) François Lamontagne et al.   BMJ-British Medical Journal

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

(2020) Andre C. Kalil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19

(2020) Carolin E. M. Jakob et al.   Scientific Data

Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection

(2018) David S. Hui   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE